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Transcriptional factors that promote formation of white adipose
tissue
Ursula A. White and Jacqueline M. Stephens*
Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA
Abstract
Adipocytes are highly specialized cells that play a major role in energy homeostasis in vertebrate
organisms. Excess adipocyte size or number is a hallmark of obesity, which is currently a global
epidemic. Obesity is a major risk factor for the development of type II diabetes (T2DM),
cardiovascular disease, and hypertension. Obesity and its related disorders result in dysregulation
of the mechanisms that control the expression of metabolic and endocrine related genes in
adipocytes. Therefore, understanding adipocyte differentiation is relevant not only for gaining
insight into the pathogenesis of metabolic diseases, but also for identifying proteins or pathways
which might be appropriate targets for pharmacological interventions. Significant advances
towards an understanding of the regulatory processes involved in adipocyte differentiation have
largely been made by the identification of transcription factors that contribute to the adipogenic
process. It is important to note that the developmental origin of white and brown fat is distinct and
different precursor cells are involved in the generation of these different types of adipose tissue
(reviewed in Lefterova and Lazar, 2009; Seale et al., 2009). Several transcription factors, notably
PPARγ, several members of the C/EBP and KLF families, STAT5, and SREBP-1c, have been
shown to have significant roles in promoting adipogenesis. More comprehensive reviews on
negative and positive regulators of adipogenesis have been published in the past year (reviewed in
Christodoulides et al., 2009; Lefterova and Lazar, 2009). Though many proteins are known to
negatively regulate adipogenesis, including Wnts, KLFs, the E2F family of transcription factors,
CHOP, Delta-interacting protein A, ETO/MTG8, and members of the GATA and forkhead
transcription factor families, this review will focus on transcription factors that positively impact
the development of white adipose tissue.
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1. Introduction and history
Interestingly, the majority of studies that have identified transcriptional regulators of
adipogenesis have been performed in vitro. These studies have been primarily conducted in
the 3T3-L1 or 3T3-F442A murine preadipocyte cell lines that were originally generated in
the laboratory of Dr. Howard Green at Harvard University (Green and Kehinde, 1975,
1976). In the last 35 years, these cells lines have been used by thousands of investigators
world-wide. Many cell types cannot be adequately studied in vitro because the cultured cells
do not possess the properties of cells in vivo. However, the preadipocyte cell lines
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developed by Dr. Green have been extremely useful model systems for adipocyte biologists,
and the data obtained in these cells have been validated from less mechanistic in vivo studies
in the last decade. In vivo, adipocytes have three primary characteristics, which include lipid
storage, insulin sensitivity, and endocrine properties. The 3T3-L1 cells have all three of
these notable characteristics of fat cells. In addition to being widely used to study adipocyte
development, the identity and/or characterization of many adipocyte specific genes have
been identified using this cell line.
In the late 1980s, a commentary by Dr. Steven McKnight, now at the Carnegie Institution of
Washington, and Dr. M. Daniel Lane at John Hopkins University indicated that C/EBPα was
a key metabolic regulator of energy metabolism (McKnight et al., 1989). Numerous studies
have since confirmed the role of C/EBPα and other C/EBP family members in energy
balance and defined roles for these transcription factors in adipocyte differentiation
(reviewed in Farmer, 2006). In 1994, two prominent laboratories independently identified
PPARγ as an important modulator of adipocyte differentiation. Studies by Dr. Mitch Lazar’s
group at the University of Pennsylvania observed the induction of PPARγ during
adipogenesis (Chawla et al., 1994), and experiments by Dr. Bruce Speigelman’s Laboratory
at Harvard Medical School revealed that PPARγ was a transcription factor which bound to
an enhancer element in the aP2 promoter and conferred its fat-specific expression (Tontonoz
et al., 1994). The early 1990s was also the time that Drs. Michael Brown and Joseph
Goldstein from the University of Texas Southwestern identified SREBP-1 (Yokoyama et al.,
1993), also termed ADD1, whose expression was observed to play a role in adipocyte
determination by the Spiegelman Laboratory (Tontonoz et al., 1993). Since then, several
other transcription factors have been found to promote adipocyte development.
Studies of the aP2 gene, and use of its regulatory sequences, have led to significant
discoveries in adipocyte biology and metabolic diseases. aP2 is an abundantly expressed
adipocyte gene that was first discovered in 1984 (Bernlohr et al., 1984), and one of the
earliest studies on PPARγ identified this transcription factor for its ability to bind to an
enhancer element in the aP2 promoter and mediate its adipocyte-enriched expression
(Tontonoz et al., 1994). Since its discovery, the aP2 promoter has been used by hundreds of
laboratories to construct transgenes that have largely fat-specific expression. A lesser known
historical fact is that c-fos was also shown to bind to the aP2 promoter just 124 base pairs
upstream of the transcriptional start site (Distel et al., 1987). As means of introduction, this
was one of the first studies to propose that AP-1 proteins were regulators of adipocyte gene
expression.
1.1. AP-1 transcription factors
Members of the activating protein-1 (AP-1) family of transcription factors are well-known
regulators of cellular proliferation and differentiation. AP-1 is a collective term referring to
dimeric transcription factors composed of c-Jun, Jun-B, Jun-D and c-Fos, Fos-B, Fra-1, or
Fra-2 subunits that bind to a common DNA site, the AP-1-binding site (reviewed in Karin et
al., 1997). Initial studies by the Spiegelman Laboratory showed that c-Fos was involved in
the modulation of aP2 expression (Distel et al., 1987), and accordingly it was shown that the
expression of c-Jun, c-Fos, Jun-B, Fos-B, and Fra-1 was induced immediately after the
induction of adipocyte differentiation (Stephens et al., 1992, 1993). Although the role of
individual AP-1 family members in adipogenesis has not been elucidated, there is strong
evidence to indicate the importance of these transcription factors in vivo. Transgenic mice
were generated that express a dominant-negative protein that prevents the DNA binding of
B-ZIP transcription factors of both the C/EBP and Jun families under the control of the
adipose-enriched aP2 enhancer/promoter. These mice have no white adipose tissue
throughout life (Moitra et al., 1998). Collectively, these studies suggest that the induction
and expression of AP-1 transcription factors play a role in fat cell differentiation.
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1.2. STAT (signal transducers and activators of transcription)
In the last decade, several groups have studied the modulation and function of STAT
proteins during adipogenesis and in mature fat cells. The STAT family of mammalian
transcription factors is comprised of seven proteins (STATs 1, 2, 3, 4, 5A, 5B, and 6) which,
in response to stimulation of various receptors, mainly those for cytokines, are
phosphorylated on tyrosine residues causing their translocation to the nucleus. Each STAT
family member shows a distinct pattern of activation by cytokines and upon nuclear
translocation can regulate the transcription of particular genes (reviewed in Darnell, 1997).
STATs have been shown to bind to distinct DNA sequences, and this binding regulates the
transcription of specific genes (reviewed in Darnell, 1997; Pellegrini and Dusanter-Fourt,
1997). Since the tissue distribution and function of each STAT is unique, the regulation of
tissue-specific genes appears to be a physiological role for these proteins (reviewed in
Schindler and Darnell, 1995). This hypothesis is supported by numerous reports which
demonstrate that specific STATs are activated differently by growth factors and cytokines,
and STAT activation can be cell type dependent. In addition, transgenic knockout
experiments have revealed crucial roles for each known mammalian STAT (reviewed in
Darnell, 1997), and cell-specific functions for STAT family members have also been
identified (reviewed in Schindler, 2002).
The first studies on STAT expression in 3T3-L1 cells revealed that STATs 1, 5A and 5B
were highly induced during murine adipogenesis (Stephens et al., 1996). Similar results
were observed during the in vitro differentiation of human preadipocytes (Harp et al., 2001).
In addition, the ectopic expression of C/EBPs β and δ in non-precursor cells results in an
induction of adipogenesis (Wu et al., 1996) that is accompanied by an induction in STAT5A
and STAT5B protein levels (Stephens et al., 1996). These two STAT5 proteins are also
coordinately regulated with both PPARγ and C/EBPα in differentiating 3T3-L1 cells under a
variety of conditions (Stewart et al., 1999). In 3T3-F442A preadipocytes, the ability of
growth hormone to modulate adipogenesis is attenuated by STAT5 anti-sense
oligonucleotides (Yarwood et al., 1999). Also, constitutively active STAT5 is capable of
replacing the requirement for growth hormone in adipogenesis of these cells (Shang and
Waters, 2003). Ectopic expression of STAT5A confers adipogenesis in 3T3-L1
preadipocytes (Nanbu-Wakao et al., 2002) and in two different non-precursor cell lines
(Floyd and Stephens, 2003). Interestingly, STAT5B was not capable of conferring
adipogenesis in non-precursor cells (Floyd and Stephens, 2003). Transgenic deletion of
STAT5A, STAT5B, or both STAT5 genes in mice resulted in significantly reduced fat pad
sizes compared to wild-type mice (Teglund et al., 1998). In primary cultures of adipose
tissue from these animals, growth hormone did not stimulate lipolysis as it did in adipocytes
from wild-type animals (Fain et al., 1999), suggesting that some of the effects of growth
hormone on fat metabolism are dependent on STAT5 proteins. It should be noted that the
increased expression of STAT5 proteins is not typically observed until after the induction of
C/EBPα and PPARγ (refer to Fig. 1), yet the activation of STAT5 proteins in preadipocytes
occurs prior to the induction in expression of PPARγ in 3T3-L1 cells (Floyd and Stephens,
2003). In fact, both STAT5 proteins are tyrosine phosphorylated and translocate to the
nucleus within 15 min after the induction of adipogenesis (Baugh et al., 2007; Floyd and
Stephens, 2003). Coupled with the observations that STAT5 null mice have fat pads one-
fifth normal size (Teglund et al., 1998), the data suggest that activation of STAT5 proteins
may be an important driver of adipogenesis both in vitro and in vivo. This hypothesis is also
supported by work indicating that one of the PPARγ promoters can be modulated by STAT5
(Kawai et al., 2007), which indicates that STAT5 activation might drive adipogenesis by
inducing PPARγ expression. In summary, work by a variety of laboratories has
demonstrated that STAT5 proteins are activated and induced during adipogenesis and play
an important role in adipose tissue development.
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1.3. Krüppel-like factors (KLFs)
Krüppel-like zinc finger transcription factors (KLFs) are known to play diverse roles in cell
differentiation and development in mammals. One protein in the KLF family, KLF15, was
shown to be highly induced during adipocyte differentiation, and inhibition of KLF15
function or expression is accompanied by an inhibition of adipogenesis in 3T3-L1 cells
(Mori et al., 2005). These studies also revealed that KLF15 could confer adipogenesis in
non-precursor cells and result in the induction of PPARγ expression. Similar to KLF15,
KLF5 expression is also highly induced during adipocyte differentiation in 3T3-L1 cells
(refer to Fig. 1), and embryonic fibroblasts obtained from heterozygote KLF5 mice exhibit
reduced adipogenesis (Oishi et al., 2005). KLFs are not only involved in lipid accumulation,
but also appear to play a role in the ability of the adipocyte to be insulin sensitive, as
indicated by studies showing that KLF15 is important in the expression of GLUT4 (Gray et
al., 2002). KLF4 is also induced early in the differentiation process and can transactivate the
C/EBPβ promoter in cooperation with Krox20 (Birsoy et al., 2008), another zinc finger
transcription factor shown to stimulate adipogenesis (Chen et al., 2005). KLF6 has been
shown to have a favorable effect on adipogenesis by inhibiting dlk1, an inhibitor of fat cell
differentiation (Li et al., 2005). Other members of the KLF family have been shown to have
negative effects on adipogenesis. Emerging studies on the role of KLFs in adipocyte
development will be critical for the identification of target genes in fat cells, as well as the
likely discovery of both redundant and non-redundant functions of these transcription factors
in adipocytes.
1.4. Sterol regulatory element binding proteins (SREBPs)
In 1993, studies by the Spiegelman group identified a basic helix-loop-helix transcription
factor that was expressed in adipocytes and regulated during adipogenesis (Tontonoz et al.,
1993). The protein was called ADD1 for adipocyte differentiation and determination. Two
months later, this protein was labeled SREBP-1 by the Brown and Goldstein Laboratories,
who named the transcription factor for its ability to bind sterol responsive elements within
the promoter of the LDL receptor gene (Yokoyama et al., 1993). It is now known that there
are three SREBP isoforms (SREBP-1a, -1c, and -2) that have been well characterized.
SREBP-1a and -1c are transcribed from the same gene, each by a distinct promoter, and the
predominant SREBP-1 isoform in liver and adipose tissue is SREBP-1c. SREBP-2 is
relatively selective in the transcriptional activation of cholesterol biosynthetic genes, and
SREBP-1c has a greater role in regulating genes associated with fatty acid synthesis
(reviewed in Eberle et al., 2004). Although there is clear evidence that SREBP is an insulin
modulated transcription factor that is involved in the regulation of genes associated with
cholesterol and lipid metabolism, studies indicate that SREBPs may not be critical for
adipogenesis. Mice deficient in SREBP-1 do not have a significantly decreased amount of
white adipose tissue, but SREBP-2 levels were increased, suggesting it might compensate
for SREBP-1 in this animal model (Shimano et al., 1997). These in vivo studies are
supported by additional transgenic studies where SREBP-1 deficient mice were crossed with
ob/ob (leptin deficient) mice, and it was found that SREBP-1 was not required for the
development of obesity (Yahagi et al., 2002). These observations concluded that SREBP-1
regulation of lipogenesis was highly involved in the development of fatty livers but was not
a determinant of obesity in this animal model (Yahagi et al., 2002). However, ectopic
expression of a dominant-negative SREBP-1c was shown to attenuate adipocyte
differentiation (Kim and Spiegelman, 1996). In addition, over expression of SREBP-1c
enhanced the adipogenic activity of PPARγ (Kim and Spiegelman, 1996), and other studies
suggest that SREBP-1c contributes to the generation of PPARγ ligands (Kim et al., 1998). In
summary, in vitro studies support a role for SREBP-1 in adipogenesis, whereas in vivo
studies indicate that SREBPs are not required for the production or expansion of adipose
tissue.
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1.5. C/EBP (CAAAT enhancer binding proteins)
C/EBP transcription factors were the first family of transcription factors shown to play a
critical role in the differentiation of fat cells in vitro. Today, we know that transgenic mice
lacking both C/EBPβ and C/EBPδ or C/EBPα alone have defective adipocyte differentiation
(Tanaka et al., 1997; Wang et al., 1995). Prior to these in vivo observations, the cascade of
induction of these three C/EBP family members was revealed by McKnight and
collaborators who showed that C/EBPs β and δ were induced immediately after the
induction of differentiation, whereas C/EBPα expression did not occur until 4–5 days after
the initiation of differentiation (Cao et al., 1991) (refer to Fig. 1). This group also
demonstrated that C/EBPs β and δ were responsible for inducing C/EBPα expression (Yeh et
al., 1995). Ectopic expression studies conducted by several laboratories demonstrated the
adipogenic capabilities of C/EBPα or C/EBPβ alone, or in the presence of C/EBPδ (Lin and
Lane, 1994; Wu et al., 1995, 1996; Yeh et al., 1995). Today, C/EBPα and PPARγ are
considered the two primary transcription factors that mediate adipogenesis. However, cells
lacking C/EBPα are capable of adipogenesis, but are not insulin sensitive (el Jack et al.,
1999; Wu et al., 1999). Similar to SREBP-1c, there is evidence to indicate that C/EBPs may
play a role in the induction of PPARγ ligands (Hamm et al., 2001). In summary, both in
vitro and in vivo studies indicate a substantial role for C/EBPβ, C/EBPδ, and C/EBPα in
adipogenesis. Although C/EBPα may not be absolutely required for lipid accumulation, this
transcription factor clearly plays a role in conferring insulin sensitivity in adipocytes.
1.6. PPAR[CR] (peroxisome proliferator-activated receptors[CR])
Although a number of transcription factors, including those mentioned above, have been
shown to have profound effects on fat cell differentiation and the expression of adipocyte
genes, only one adipocyte transcription factor has been shown to be necessary for
adipogenesis. Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of
the nuclear hormone receptor superfamily that is required for the development of adipocytes,
and deletion of PPARγ in mice results in placental dysfunction and embryonic lethality
(Barak et al., 1999; Rosen et al., 1999). As previously noted, PPARγ was identified as a
transcription factor induced during differentiation that bound an enhancer element within the
aP2 promoter (Tontonoz et al., 1994). Although PPARγ is critical for adipogenesis, this
transcription factor is induced after several other key transcriptional modulators of
adipogenesis (Fig. 1). A remarkable finding in 1995 was that the insulin sensitizing drugs
thiazolidinediones were ligands for PPARγ (Lehmann et al., 1995). This molecular study
was pivotal in enhancing our understanding of the contributions of adipose tissue in insulin
responsiveness. Many investigators were surprised to learn that activating a transcription
factor whose expression was highly enriched in fat cells could contribute to whole animal
insulin sensitivity. It is now known that adipocytes secrete several hormones that can affect
the activity of other tissues, and studies of PPARγ have revealed that modulation of this
transcription factor can contribute to systemic insulin resistance. Although PPARγ null mice
are embryonic lethal (Barak et al., 1999; Rosen et al., 1999), transgenic mice lacking PPARγ
specifically in adipose tissue exhibit greatly reduced sized fat pads and insulin resistance in
fat and liver (He et al., 2003). However, PPARγ heterozygote mice have enhanced insulin
sensitivity (Miles et al., 2000). Together, these studies suggest that the amount of PPARγ in
adipose tissue is physiologically relevant.
In the last several years, several studies have examined pathways that are involved in
regulating the levels of PPARγ. In particular, the ubiquitin–proteasome system has emerged
as an important regulator of PPARγ proteins (Floyd and Stephens, 2002; Hauser et al.,
2000). In addition, a role for the ubiquitin-like protein, SUMO (Small Ubiquitin-like
Modifier) in regulating PPARγ has been demonstrated by several groups (Floyd and
Stephens, 2004; Ohshima et al., 2004; Pascual et al., 2005; Yamashita et al., 2004). The
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phosphorylation of PPARγ by MAPKs is also an important modulator of the activity of this
transcription factor (reviewed in Burns and Vanden Heuvel, 2007). Although PPARγ
knockdown prevents adipocyte differentiation, a recent study has indicated that PPARγ is
not required for the maintenance of the differentiated adipocyte after the cells have
undergone adipogenesis (Liao et al., 2007). These observations are supported by many
anecdotal observations that indicate that PPARγ expression is decreased as adipocytes age in
vitro. In addition, the increase of life span via caloric restriction results in the induction of
Sirt1, a transcriptional modulator with deacetylase activity that represses PPARγ activity in
vivo (Picard et al., 2004). This study also demonstrated that the repression of PPARγ by
Sirt1 was evident in 3T3-L1 adipocytes. Collectively, studies by numerous laboratories have
demonstrated the adipogenic capabilities of PPARγ; however, the role of this transcription
factor in mature adipocytes is less understood. Nonetheless, PPARγ expression and activity
are controlled at multiple levels, including alternative promoter usage, tissue limited
expression, phosphorylation, acetylation, ubiquitylation, and SUMOylation. The multiple
levels of regulation of this transcription factor suggest that controlling the amount and
activity of PPARγ is essential. The role of PPARγ in the development and treatment of
diabetes is well established (reviewed in Leff et al., 2004), and the importance of PPARγ in
humans is indicated by several loss-of-function mutations in the PPARγ gene that cause
lipodystrophy and diabetes (Barroso et al., 1999; Doney et al., 2004; Monajemi et al., 2007;
Semple et al., 2006).
Conclusions
In addition to the transcription factors described above that promote adipogenesis, there are
several other transcription factor families that have been shown to have positive or negative
effects on adipocyte differentiation (reviewed in Farmer, 2006; Lefterova and Lazar, 2009).
The expression and activity of these transcription factors play a profound role in modulating
a vast array of target genes that are important in conferring lipid accumulation, insulin
sensitivity, and endocrine properties in mature fat cells. The identification and
characterization of the target genes of adipogenic transcription factors has provided critical
information in understanding the role of these proteins in both adipocyte differentiation and
in adipose tissue. In summary, adipogenesis of white preadipocytes occurs as a result of a
transcriptional cascade that involves the tightly regulated induction of numerous
transcription factors, including STAT5, SREBP-1c, PPARγ and several members of the C/
EBPs and KLF families (refer to Fig. 1). In addition, many of these adipogenic factors
possess the ability to regulate one another’s gene expression, and there is substantial
evidence to support functional redundancy in the ability of some of these transcription factor
families to confer adipocyte development in vitro and in vivo. The future study of
transcription factors that modulate adipocyte development and function is important and will
likely continue to provide insight into our understanding of metabolic diseases including
obesity and type II diabetes.
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